Rachel McMinn

Insider Reports History

Location
New York, NY
Signature
/s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Rachel McMinn:

Company Role Class Num Shares Value Price $ Report Date Ownership
Neurogene Inc. Chief Executive Officer, Director Common Stock 1,274,259 $21,585,947 $16.94 26 Mar 2025 Direct
Neurogene Inc. Chief Executive Officer, Director Employee Stock Option (Right to buy) 143,500 26 Mar 2025 Direct

Insider Reports Filed by Rachel McMinn

Symbol Company Period Transactions Value $ Form Type Role Filing Time
NGNE Neurogene Inc. 26 Mar 2025 2 $0 4 Chief Executive Officer, Director 28 Mar 2025, 21:27
NGNE Neurogene Inc. 22 Nov 2024 1 +$969,000 4 Chief Executive Officer, Director 25 Nov 2024, 21:29
NGNE Neurogene Inc. 13 Mar 2024 1 $0 4 Chief Executive Officer, Director 14 Mar 2024, 20:54
NGNE Neurogene Inc. 18 Dec 2023 0 $0 3 Chief Executive Officer, Director 26 Dec 2023, 18:12